Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses (2010 - 2020)

Regeneron Pharmaceuticals has reported Other Accumulated Expenses for 10 years, with the latest figure at $122.4 million in Q4 2020.

• For the quarter ending Q4 2020, Other Accumulated Expenses rose 44.0% year-over-year to $122.4 million; the trailing twelve-month figure through Dec 2020 stood at $122.4 million (up 44.0% YoY), and the FY2020 full-year result was $122.4 million, up 44.0% from the prior year.
• Other Accumulated Expenses for Q4 2020 stood at $122.4 million, up from $96.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $122.4 million in Q4 2020, with the low at $267000.0 in Q4 2017.
• Average Other Accumulated Expenses over 4 years is $39.8 million, with a median of $3.7 million recorded in 2016.
• Year-over-year, Other Accumulated Expenses jumped 518.22% in 2016 and sank 93.51% in 2017.
• Tracing REGN's Other Accumulated Expenses over 4 years: stood at $1.2 million in 2016, then slumped by 77.33% to $267000.0 in 2017, then soared by 31735.21% to $85.0 million in 2019, then soared by 44.0% to $122.4 million in 2020.
• The last three Other Accumulated Expenses figures came in at $122.4 million (Q4 2020), $96.9 million (Q3 2020), and $103.8 million (Q2 2020), per Business Quant data.

Peer Comparison